Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04074837 · ClinicalTrials.gov registry record · Phase 1
Phase1a, Dose-escalation Study of NNI-362 in Healthy Aged Volunteers
A Phase 1 study of Alzheimer Disease, sponsored by Neuronascent.
- Completed
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
- 1
- Study location
NCT04074837: Completed Phase 1 study of Alzheimer Disease, sponsored by Neuronascent.
NCT04074837 is a Phase 1 study of Alzheimer Disease that has completed, run by Neuronascent. The registered enrollment target is 56 participants, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04074837, a Phase 1 study of Alzheimer Disease, has completed, sponsored by Neuronascent.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to examine the safety, tolerability and pharmacokinetics of single and multiple doses of NNI-362 in healthy aged population.
Primary Outcome
To examine the number of participants with treatment-related adverse events according to criteria of CTCAE v4.0
Conditions Studied
Interventions
- DRUG Placebo
- DRUG NNI-362
Study Locations (1)
California
- Parexel, International - Glendale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2019-08-01 |
| Est. Completion | 2021-08-15 |
| Phase | Phase 1 |
What the finished NCT04074837 record still lists
NCT04074837 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 56 participants, a relatively small participant target, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Alzheimer Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04074837 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT04074837 about?
NCT04074837 is a clinical study titled "Phase1a, Dose-escalation Study of NNI-362 in Healthy Aged Volunteers". The purpose of this study is to examine the safety, tolerability and pharmacokinetics of single and multiple doses of NNI-362 in healthy aged population.
What is the current status of trial NCT04074837?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2019-08-01. Estimated completion is 2021-08-15.
What conditions does trial NCT04074837 study?
This clinical trial studies the following conditions: Alzheimer Disease.
What interventions are being tested in trial NCT04074837?
The interventions under investigation include: Placebo (DRUG), NNI-362 (DRUG).
Who is sponsoring clinical trial NCT04074837?
This trial is sponsored by Neuronascent, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04074837 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04074837's enrollment target sits among peer trials
56 202nd of 306 higher than 105 of 306 other Alzheimer Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alzheimer Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease
RECRUITING · Phase 1
-
Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules Compared to the Original Formulation of NPT 2042
RECRUITING · Phase 1
-
Nicotinic Acid for the Treatment of Alzheimer's Disease
RECRUITING · Phase 1
-
A Phase Ia/Ib, First-in-human (FIH) Study for Safety, Tolerability, Pharmacokinetics (PK), and Clinical Activity Evaluation of ADEL-Y01
RECRUITING · Phase 1
-
Deep Repetitive Transcranial Magnetic Stimulation (rTMS) of the Precuneus for Alzheimer Disease (AD)
RECRUITING · Phase 1
-
Assess Fibrin in Brains With AD/ADRD
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02287428 · 56 participants · Phase 1
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
- NCT02923011 · 56 participants · Phase 3
Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas
- NCT02935283 · 56 participants
Neuroimaging and Neuropsychological Outcomes in Urea Cycle Disorders
- NCT03375866 · 56 participants · NA
Effects of Mixed Nut Consumption on Satiety and Weight Management
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI